The majority of the proteins investigated did not show consistent changes in their expression in the three glioma stem cell lines treated with RG7112 or meaningful changes considering their roles in the regulation of apoptosis; however, RG7112 increased the expression of BAX and PUMA, multi-domain and BH3-only pro-apoptotic members of the BCL2 family, respectively [25], and reduced that of survivin (Figure 5A), all of which are known targets of p53 transcriptional activation (BAX [26,27] and PUMA [28,29,30]) and repression (survivin [31,32,33,34]). The gene discussed is BCL2; the disease is central nervous system cancer.